Samsung Biologics Co.,Ltd. (KRX:207940)

Samsung Biologics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	709,479	391,222	367,937	890,820	47,410	28,850
Short-Term Investments	935,210	940,067	1,688,338	2,204,212	473,985	323,156
Trading Asset Securities	-	-	-	98,506	850,040	500,046
Cash & Short-Term Investments	1,644,689	1,331,289	2,056,276	3,193,537	1,371,435	852,052
Cash Growth	4.85%	-35.26%	-35.61%	132.86%	60.96%	23.50%
Accounts Receivable	-	-	-	-	0	-
Receivables	-	-	-	-	0	400
Inventory	3,077,186	2,818,276	2,641,368	2,375,819	1,012,871	645,960
Prepaid Expenses	25,093	28,251	26,830	23,201	8,579	7,124
Other Current Assets	961,947	1,340,302	797,513	865,099	430,291	245,811
Total Current Assets	5,708,916	5,518,118	5,521,988	6,457,657	2,823,175	1,751,347
Property, Plant & Equipment	6,219,306	5,837,482	4,342,424	3,871,452	2,227,687	1,760,728
Long-Term Investments	61,078	59,605	47,435	38,110	2,661,499	2,634,603
Goodwill	1,677,608	1,677,608	1,677,608	1,677,608	-	-
Other Intangible Assets	1,025,133	1,294,705	1,580,423	1,541,850	32,172	23,345
Long-Term Accounts Receivable	-	0	0	-0	0	-0
Long-Term Deferred Tax Assets	152.33	165.09	-	-	-	-
Long-Term Deferred Charges	2,747,252	2,592,990	2,574,057	2,741,848	-	-
Other Long-Term Assets	334,170	355,592	302,236	253,524	225,477	253,879
Total Assets	17,773,644	17,336,296	16,046,197	16,582,050	7,970,011	6,424,201
Accounts Payable	215,714	177,992	201,709	59,616	32,251	54,984
Accrued Expenses	689,366	545,403	281,317	207,437	74,322	64,356
Short-Term Debt	207,000	207,000	654,500	582,783	50,000	30,000
Current Portion of Long-Term Debt	75,000	120,000	733,405	556,017	109,855	160,907
Current Portion of Leases	73,367	138,594	144,031	142,247	7,537	6,533
Current Income Taxes Payable	287,476	375,388	191,212	223,299	110,174	23,260
Current Unearned Revenue	482,365	400,007	399,818	432,680	-	-
Other Current Liabilities	1,613,674	1,888,804	1,551,870	1,977,462	723,156	249,261
Total Current Liabilities	3,643,961	3,853,188	4,157,861	4,181,542	1,107,295	589,301
Long-Term Debt	1,058,130	1,012,757	239,783	965,090	1,114,684	571,451
Long-Term Leases	4,380	7,889	137,614	267,896	10,671	16,014
Long-Term Deferred Tax Liabilities	897,911	972,062	1,184,420	1,214,216	487,712	449,847
Other Long-Term Liabilities	549,753	580,177	490,910	968,833	258,547	198,804
Total Liabilities	6,170,850	6,431,620	6,215,705	7,597,576	2,978,909	1,825,418
Common Stock	177,935	177,935	177,935	177,935	165,413	165,413
Additional Paid-In Capital	5,663,111	5,663,111	5,663,111	5,663,111	2,487,313	2,487,313
Retained Earnings	5,786,548	5,086,609	4,003,293	3,145,601	2,347,187	1,953,598
Comprehensive Income & Other	-24,801	-22,979	-13,847	-2,173	-8,811	-7,540
Total Common Equity	11,602,794	10,904,676	9,830,492	8,984,474	4,991,102	4,598,783
Shareholders' Equity	11,602,794	10,904,676	9,830,492	8,984,474	4,991,102	4,598,783
Total Liabilities & Equity	17,773,644	17,336,296	16,046,197	16,582,050	7,970,011	6,424,201
Total Debt	1,417,877	1,486,239	1,909,333	2,514,033	1,292,747	784,905
Net Cash (Debt)	226,811	-154,951	146,943	679,504	78,688	67,147
Net Cash Growth	-	-	-78.38%	763.54%	17.19%	85.40%
Net Cash Per Share	3186.72	-2177.07	2064.56	9733.67	1189.27	1014.84
Filing Date Shares Outstanding	71.17	71.17	71.17	71.17	66.17	66.17
Total Common Shares Outstanding	71.17	71.17	71.17	71.17	66.17	66.17
Working Capital	2,064,954	1,664,929	1,364,127	2,276,115	1,715,881	1,162,046
Book Value Per Share	163020.12	153211.51	138119.15	126232.53	75434.17	69504.77
Tangible Book Value	8,900,052	7,932,363	6,572,461	5,765,016	4,958,931	4,575,439
Tangible Book Value Per Share	125046.40	111450.29	92343.57	80998.90	74947.94	69151.95
Land	141,291	141,114	141,065	141,065	-	-
Buildings	3,506,535	1,956,958	1,943,694	1,376,222	832,519	792,906
Machinery	3,277,540	2,629,598	2,525,344	1,811,982	1,380,919	1,295,244
Construction In Progress	169,106	1,833,097	202,411	825,199	583,360	105,470

Source: S&P Global Market Intelligence. Standard template. Financial Sources.